Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$423.65 USD

423.65
553,842

-6.17 (-1.44%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks News

Masimo RAS-45 Full-Market Release to Boost Respiratory Care

Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

    Baxter Announces Launch of DeviceVue System for Sigma Pumps

    Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.

      Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

      The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

        STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

        STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

          Here's Why You Should Invest in Orthofix International Now

          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

            Allscripts Rides High on Product Launches Amid Rising Costs

            Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

              Omnicell (OMCL) Gains on Product Launches, Global Expansion

              The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                Align Technology (ALGN) Prospects Bright, Competition Rife

                Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                  Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                  Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.

                    PetMed Express Optimistic on New Orders Amid Stiff Rivalry

                    PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.

                      Here's Why Investors Should Buy Masimo (MASI) Right Now

                      Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.

                        Amedisys or Chemed: Which is a Better Investment Choice?

                        After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                          Why Should Investors Add Amedisys (AMED) to Their Portfolio?

                          Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

                            Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                            IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

                              Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

                              Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

                                Here's Why You Should Add Chemed (CHE) to Your Portfolio

                                Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

                                  Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                                  BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

                                    BD (BDX) Inks New Deal to Strengthen Foothold in STI Space

                                    BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.

                                      Boston Scientific MultiSENSE Study on HeartLogic Positive

                                      Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

                                        Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

                                        Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

                                          Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                                          Neogen (NEOG) rides high on balanced growth across all business segments.

                                            Halyard Health (HYH) Announces Positive Data on COOLIEF

                                            Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.

                                              TransEntrix Progresses Toward FDA Approval for Senhance

                                              TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.

                                                Surmodics Receives FDA's Approval for PTA Balloon Catheter

                                                Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                                                  Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5

                                                  Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.